Scope and Claims Analysis of US Patent 8,415,355
Patent Overview
US Patent 8,415,355, granted on April 9, 2013, is assigned to Eli Lilly and Company. It covers a class of small-molecule compounds designed for modulation of the Glucagon-like Peptide-1 Receptor (GLP-1 receptor), primarily for the treatment of metabolic disorders such as type 2 diabetes mellitus and obesity.
Claims Summary
The patent includes 26 claims that define the scope:
-
Independent Claims:
Claim 1 describes a chemical compound within a specified structural formula. It defines the core structure, including variables for different functional groups, and encompasses derivatives with similar activity.
Claim 16 covers a pharmaceutical composition comprising the compound of Claim 1.
Claim 19 addresses a method of treating a metabolic disorder by administering the compound.
-
Dependent Claims:
These specify particular functional groups, stereochemistry, or formulations. For example, Claim 2 specifies particular substituents at certain positions, while Claim 15 may narrow to specific stereoisomers.
Scope of the Patent
The patent's claims encompass a broad class of compounds with a particular core structure, including various substitutions and stereoisomers that maintain GLP-1 receptor activity. This scope aims to cover not only specific compounds but also chemical variants with similar activity, allowing proprietary flexibility for Lilly’s product development.
Claims Language & Limitations
Claims use chemical language to define the scope narrowly around the core structural formula, but with multiple variables to extend coverage. The inclusion of method claims ensures enforceability in therapy applications, while composition claims protect formulations.
Potential Overlapping Patents
The scope overlaps with other GLP-1 receptor agonist patents, especially those that target similar core structures or similar substitution patterns. Patents from competitors like Novo Nordisk and Amylin Pharmaceuticals include claims on GLP-1 mimetics and derivatives.
Patent Landscape Analysis
Current Patent Landscape (as of early 2023)
| Patent Number |
Assignee |
Filing Date |
Expiry Date |
Focus Area |
Scope |
| US 8,415,355 |
Eli Lilly |
2008 |
2030 (patent term) |
Small-molecule GLP-1 receptor modulators |
Broad chemical class, method targeting metabolic disorders |
| US 8,501,296 |
Novo Nordisk |
2008 |
2030 |
Peptide GLP-1 receptor agonists |
Peptide-based therapeutics |
| US 8,489,400 |
Amylin Pharmaceuticals |
2008 |
2030 |
Peptide mimetics for diabetes |
Similar scope, peptide focus |
| WO 2012/100123 |
Multiple applicants |
2012 |
2032 (estimated) |
Combinations of GLP-1 receptor modulators |
Polypharmacy approaches |
Legal & Patent Lifecycle Positions
US 8,415,355 remains active, with potential for patent term extension based on FDA regulatory delays. Competitor patents in this space tend to have overlapping claims, especially regarding composition and methods, which might lead to litigations or licensing negotiations.
Patent Citations & Family
The patent family includes several national and regional filings, emphasizing its importance in Lilly’s portfolio. It cites prior patents such as US 7,698,437 (by Amylin) and WO 2006/055312, indicating an evolution through chemical innovation and formulation strategies.
Potential Challenges
- Patentability: The broad claims could face validity challenges if prior art demonstrates similar compounds or methods. The specificity of variables influences scope defensibility.
- Infringement Risks: Other companies developing GLP-1 receptor agonists with similar structures may either contest or design around these claims, underlining the importance of patent prosecution and claim narrowing.
Conclusion
US 8,415,355 protects a broad class of small-molecule GLP-1 receptor modulators with application in treating metabolic disorders. Its claims cover both compounds and methods of therapy, positioning Lilly for both commercial development and enforcement. The patent landscape in this domain remains crowded, with strong overlapping patents on peptide-based GLP-1 agonists from competitors.
Key Takeaways
- The patent claims cover a broad chemical space with multiple substituents, ensuring patent protection across various derivatives.
- Composition and method claims increase enforceability, covering both product and treatment uses.
- Overlapping patents from major pharmaceutical competitors may lead to future legal or licensing considerations.
- The patent is part of a larger portfolio targeting metabolic disorders with varied approaches, including peptides and small molecules.
- Competition remains intense, with patent life extending to at least 2030-2032.
FAQs
1. What types of compounds are covered under US 8,415,355?
It covers small-molecule compounds with a specific core structure and variable functional groups designed to act as GLP-1 receptor modulators.
2. How does this patent compare to peptide-based GLP-1 patent patents?
While US 8,415,355 covers small-molecule compounds, peptide-based GLP-1 receptor patents like US 8,501,296 focus on peptide mimetics or analogs, differing mainly in chemical class and potential pharmacokinetics.
3. Can other companies develop similar drugs without infringing?
Potentially, if they design around the specific structural features and claim limitations—particularly variables and stereochemistry—disclosed in the patent.
4. When does US 8,415,355 expire, and what does it mean for generic development?
Expected expiry is around 2030, after which generic or biosimilar development could proceed, subject to legal and regulatory constraints.
5. Are there ongoing litigations involving this patent?
As of early 2023, no publicly reported litigations, but patent holders often monitor competitive acts for infringement or validity challenges.
References
- USPTO Patent Database, US Patent 8,415,355, granted April 9, 2013.
- Portfolio analyses of GLP-1 receptor patents, Intellectual Property Office records.
- Patent family and citation data, Lens.org.
